Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Radiopharm Theranostics - Appendix 4E and FY23 Financial Report (ASX:RAD)

To view the Appendix 4E and FY23 Financial Report, download the attached PDF.

Radiopharm Theranostics - TerThera Terbium-161 isotope supply agreement expanded (ASX:RAD)

SYDNEY, August 24, 2023 - Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic us...read more

Rural Funds Group - Presentation - FY23 Financial Results (ASX:RFF)

To view the presentation, download the attached PDF.

Rural Funds Group - FY23 Financial Results Summary (ASX:RFF)

Rural Funds Management Limited (RFM) today released the Rural Funds Group (ASX: RFF, the Group) Financial Statements for the year ended 30 June 2023 (FY23) as summarised below. Financial highligh...read more

Rural Funds Group - Full Year Statutory Accounts (ASX:RFF)

To view the statutory accounts, download the attached PDF.

Rural Funds Group - Independent valuation update (ASX:RFF)

Rural Funds Management Limited (RFM), the responsible entity of Rural Funds Group (RFF), provides an update on independent valuations arranged for the six months ended 30 June 2023 (2H23). RFF ha...read more

Radiopharm Theranostics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:RAD)

Highlights: -- Orphan Drug Designation granted by FDA for Ga68-Trivehexin (RAD 301) -- Successful completion of pre-Investigational New Drug (IND) meeting with the FDA concerning F18-pivalate (R...read more

Dividend/Distribution - RFF (ASX:RFF)

To view the notification, download the attached PDF.

Radiopharm Theranostics - FDA Pre-IND meeting supports an IND application for RAD 101 (ASX:RAD)

Sydney, Australia – 29 May 2023 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceuti...read more

Radiopharm Theranostics - RAD 301 receives FDA Orphan Drug Designation (ASX:RAD)

Trivehexin radiopharmaceuticals being developed for imaging and treatment of cancers expressing αvβ6-integrin Pancreatic ductal adenocarcinoma is primary indication ...read more

Radiopharm Theranostics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:RAD)

HIGHLIGHTS: Partnership with GenesisCare to develop novel radiopharmaceuticals in Australia Binding agreement to acquire Pharma15 for next generation preclinical platform of the...read more

Radiopharm Theranostics - Agreement with TerThera to supply Terbium-161 isotope (ASX:RAD)

SYDNEY, 17 April 2023 - Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses...read more

Dr Ken Herrmann appointed to RAD Scientific Advisory Board (ASX:RAD)

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic us...read more

Radiopharm Theranostics to acquire Pharma15 Corporation (ASX:RAD)

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce...read more

Dividend/Distribution - RFF (ASX:RFF)

To view the Notification of dividend / distribution, download the attached PDF.

Viewing: 31 - 45 of 200 Previous | Next